GPCR
Price
$21.19
Change
-$0.74 (-3.37%)
Updated
Oct 23 closing price
Capitalization
1.51B
11 days until earnings call
Intraday BUY SELL Signals
IMMP
Price
$3.20
Change
+$0.04 (+1.27%)
Updated
Oct 23 closing price
Capitalization
471.59M
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GPCR vs IMMP

GPCR vs IMMP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GPCR vs. IMMP commentary
Oct 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GPCR is a StrongBuy and IMMP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GPCR with price predictions
Oct 23, 2026

GPCR in +8.54% Uptrend, rising for three consecutive days on October 20, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GPCR advanced for three days, in 177 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for GPCR just turned positive on October 20, 2026. Looking at past instances where GPCR's MACD turned positive, the stock continued to rise in 28 of 37 cases over the following month. The odds of a continued upward trend are 76%.

GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for GPCR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.116) is normal, around the industry mean (3.035). P/E Ratio (-6.993) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IMMP with price predictions
Oct 23, 2026

IMMP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IMMP turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 37 of 40 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

IMMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for IMMP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.664) is normal, around the industry mean (3.035). P/E Ratio (-0.297) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMMP: Fundamental Ratings
IMMP
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GPCRIMMP
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 6 days ago
87%
Stochastic
ODDS (%)
N/A
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
75%
COMPARISON
Comparison
Oct 25, 2026
Stock price -- (GPCR: $21.19 vs. IMMP: $3.20)
Brand notoriety: GPCR and IMMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GPCR: 75% vs. IMMP: 53%
Market capitalization -- GPCR: $1.51B vs. IMMP: $471.59M
GPCR [@Biotechnology] is valued at $1.51B. IMMP’s [@Biotechnology] market capitalization is $471.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GPCR’s FA Score shows that 2 FA rating(s) are green while IMMP’s FA Score has 1 green FA rating(s).

  • GPCR’s FA Score: 2 green, 3 red.
  • IMMP’s FA Score: 1 green, 4 red.
According to our system of comparison, GPCR is a better buy in the long-term than IMMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GPCR’s TA Score shows that 4 TA indicator(s) are bullish while IMMP’s TA Score has 4 bullish TA indicator(s).

  • GPCR’s TA Score: 4 bullish, 2 bearish.
  • IMMP’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, both GPCR and IMMP are a good buy in the short-term.

Price Growth

GPCR (@Biotechnology) experienced а +0.52% price change this week, while IMMP (@Biotechnology) price change was -0.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

GPCR is expected to report earnings on Nov 05, 2026.

IMMP is expected to report earnings on Dec 02, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GPCR
Daily Signal:
Gain/Loss:
IMMP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XPRO16.931.27
+8.11%
Expro Group Holdings NV
LAND8.870.12
+1.33%
Gladstone Land Corp
CAI32.000.29
+0.91%
Caris Life Sciences Inc
OCCIN24.930.01
+0.04%
OFS Credit Company
GLE2.73-0.25
-8.39%
Global Engine Group Holding Limited

GPCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, GPCR has been loosely correlated with WVE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GPCR jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GPCR
1D Price
Change %
GPCR100%
-3.37%
WVE - GPCR
64%
Loosely correlated
-5.07%
KYMR - GPCR
63%
Loosely correlated
-0.08%
NRIX - GPCR
48%
Loosely correlated
-0.67%
OCUL - GPCR
42%
Loosely correlated
-1.66%
OLMA - GPCR
39%
Loosely correlated
-8.69%
More